Peptide Therapy: Benefits vs Side Effects — What to Weigh

Key Takeaways

• Regulatory Status: As of April 2026, peptide therapies range from FDA-approved medications (semaglutide, tirzepatide, tesamorelin, bremelanotide) with established indication-specific evidence; to compounded formulations — sermorelin is available through licensed 503A compounding pharmacies, while CJC-1295 and ipamorelin were the subject of an April 22, 2026 FDA PCAC recommendation against 503A inclusion and access is narrowing; to unapproved research compounds (BPC-157, TB-500) designated Category 2 under the February 2026 PCAC action and not eligible for 503A compounding. As of April 2026, FDA shortage determinations for semaglutide and tirzepatide have narrowed compounding access relative to the 2023–2024 period; branded FDA-approved products remain the primary legal route. Status and evidence quality vary radically by compound.
• Research Stage: FDA-approved compounds have Phase 3 trial data; compounded GH secretagogues have smaller clinical studies; tissue-repair research peptides are primarily preclinical with limited human observational data.
• Availability: Prescription only for compounded and FDA-approved compounds; licensed providers on the Superpower platform evaluate candidacy through clinical consultation and baseline lab work.
• How it works: Benefit-risk profiles are compound-specific: GLP-1 agonists modulate appetite and insulin signaling; GH secretagogues stimulate pulsatile growth hormone release; tissue-repair peptides are proposed to act on inflammatory and regenerative pathways.
• What the evidence shows: FDA-approved GLP-1 agonists have shown 15–21% mean weight reduction in the STEP and SURMOUNT trial populations, respectively; GH secretagogues show GH and IGF-1 elevation in clinical studies; tissue-repair peptides show preclinical promise but lack Phase 3 human trial evidence.

The peptide therapy category is unusual in medicine because it encompasses compounds at opposite ends of two spectra — an evidence spectrum that runs from large-trial FDA-approved drugs with data in tens of thousands of patients to research compounds studied only in rodent models, and a regulatory-access spectrum that has shifted materially in 2026 with the February BPC-157/TB-500 and April 22 CJC-1295/ipamorelin FDA Pharmacy Compounding Advisory Committee actions. A clinically useful benefit-risk assessment requires placing each compound in its correct evidentiary tier before the comparison begins. This article structures that comparison by compound class, with explicit evidence labels for each benefit claim and each risk profile.

How Peptide Therapy Works in the Body

GLP-1 receptor signaling and metabolic regulation

GLP-1 receptor agonists represent the highest-evidence tier of peptide therapeutics for metabolic disease. GLP-1 is an endogenous 30-amino-acid incretin peptide produced in intestinal L-cells. When GLP-1 receptors are activated by agonist peptides such as semaglutide, they stimulate glucose-dependent insulin secretion, suppress glucagon release, delay gastric emptying, and reduce appetite through hypothalamic signaling. This multi-pathway mechanism produces both glycemic benefit and weight reduction. DeFoor and Dekker, writing in Arthroscopy in 2025, framed injectable therapeutic peptides as a class with diverse pharmacological properties, with GLP-1 agonists representing the most clinically mature category.

GH axis stimulation via secretagogue mechanism

Growth hormone secretagogues work through two distinct receptor families. GHRH analogs (sermorelin, CJC-1295, tesamorelin) bind pituitary GHRH receptors and stimulate GH synthesis and release. GHRP class peptides (ipamorelin) bind ghrelin receptors and release GH through a separate but complementary pathway. Both classes stimulate pulsatile GH release that mirrors the body's natural rhythm, in contrast to exogenous GH administration, which delivers a supraphysiological bolus. Raun and colleagues, in their foundational 1998 characterization of ipamorelin in the European Journal of Endocrinology, reported that ipamorelin stimulates GH release with high selectivity, without meaningful ACTH or cortisol stimulation — a safety advantage over earlier GHRPs. Downstream, GH secretagogues elevate IGF-1, which mediates many of the anabolic and metabolic effects attributed to this class.

Tissue repair: proposed mechanisms for BPC-157 and thymosin beta-4

Research peptides with proposed tissue-repair effects are mechanistically distinct from GH axis or GLP-1 class compounds. BPC-157 is proposed to act through FAK-paxillin pathway activation, promoting fibroblast migration and tendon outgrowth. Chang and colleagues, publishing in the Journal of Applied Physiology in 2011, demonstrated this pathway in tendon fibroblast cultures. Rahman and colleagues, in a 2026 review in JAAOS Global Research & Reviews, described how therapeutic peptides are proposed to act through PI3K/Akt, mTOR, and MAPK pathways, with preclinical evidence for regenerative effects across musculoskeletal tissue that has not been confirmed in adequate human clinical trials. These are proposed mechanisms from preclinical and in vitro data; they have not been validated in adequate human clinical trials.

Sexual health peptides: melanocortin receptor pathways

Bremelanotide (PT-141) acts through melanocortin receptor 4 (MC4R) in the central nervous system to modulate sexual arousal. Mayer and Lynch, writing in the Annals of Pharmacotherapy in 2020, published the bremelanotide approval summary, documenting FDA approval of bremelanotide as a subcutaneous auto-injector for hypoactive sexual desire disorder in premenopausal women — documenting a clearly defined central nervous system mechanism of action for an FDA-approved peptide.

Who Is a Candidate for Peptide Therapy?

Who providers typically evaluate

Providers typically consider peptide therapy for individuals who:

• Have documented GH axis insufficiency — confirmed by IGF-1 testing below the age-adjusted reference range — and clinical symptoms consistent with adult GH deficiency
• Have obesity or overweight with weight-related comorbidities, evaluated for GLP-1 agonist therapy under FDA-approved criteria or for GH secretagogue therapy under clinical assessment
• Have HIV-associated lipodystrophy with visceral adipose tissue accumulation, for whom tesamorelin has FDA-approved indications
• Have hypoactive sexual desire disorder and meet criteria reviewed by a provider for bremelanotide consideration
• Are in supervised clinical settings exploring off-label use of compounded peptides with a defined monitoring plan and informed understanding of the evidence tier

Licensed providers on the Superpower platform evaluate candidacy through clinical consultation and baseline lab work.

Who should not use peptide therapy

Contraindications vary by compound class, but the following represent commonly cited exclusion criteria across multiple therapy types:

• Active or suspected malignancy — IGF-1 elevation from GH secretagogue therapy may theoretically support tumor proliferation through growth-signaling pathways; this is a mechanistic concern, not a confirmed clinical finding, but warrants provider evaluation before prescribing
• Pregnancy and breastfeeding — no clinical safety data exists for any peptide class discussed in this article in pregnant or breastfeeding populations
• Poorly controlled type 1 or type 2 diabetes — GH secretagogues reduce insulin sensitivity; glucose monitoring is required if prescribed; this is a relative, not absolute, contraindication in some clinical frameworks
• Serious cardiovascular disease without GLP-1 agonist candidacy evaluation — GLP-1 agonists have cardiovascular trial data but are initiated under cardiologist or endocrinologist guidance in high-risk populations
• Anyone sourcing peptides from non-licensed channels — grey-market research peptides have documented contamination risks that make clinical candidacy assessment irrelevant

This is not an exhaustive list. A licensed provider evaluates individual risk factors, current medications, and lab values before prescribing.

Peptide Therapy and the Evidence: Benefits by Compound Class

GLP-1 receptor agonists: weight and cardiovascular outcomes [Human RCT]

Among peptide therapeutics, GLP-1 receptor agonists have the most extensive phase 3 clinical trial evidence base. In the STEP 1 trial, published in the New England Journal of Medicine in 2021, 1,961 adults with obesity or overweight received weekly subcutaneous semaglutide 2.4 mg or placebo for 68 weeks, achieving a mean body weight reduction of 14.9% in the semaglutide group versus 2.4% with placebo. Cardiovascular benefit was subsequently demonstrated in the SELECT trial, where semaglutide reduced major adverse cardiovascular events by 20% in 17,604 adults with overweight or obesity without diabetes over a median of 33 months. In the treatment of HIV-associated lipodystrophy, the Phase III tesamorelin trial by Falutz and colleagues, published in the Journal of Acquired Immune Deficiency Syndromes in 2010, enrolled 404 HIV-positive patients and found a 10.9% reduction in visceral adipose tissue versus 0.6% with placebo over 6 months — the evidence base that earned tesamorelin its FDA approval.

GH secretagogues: body composition and GH axis restoration [Human RCT — limited scale]

Compounded GH secretagogues have smaller but clinically meaningful human evidence. Teichman and colleagues, in a 2006 RCT in the Journal of Clinical Endocrinology and Metabolism, demonstrated that CJC-1295 produced 2- to 10-fold GH increases and 1.5- to 3-fold IGF-1 increases in healthy adults, sustained for 6 to 11 days after a single injection. Sinha and colleagues, in a 2020 review in Translational Andrology and Urology, examined GH secretagogues for body composition management in hypogonadal men, reporting fat mass and lean mass improvements. Sigalos and Pastuszak, writing in Sexual Medicine Reviews in 2018, reviewed GH secretagogue safety and efficacy across clinical uses, noting general tolerability with primary monitoring concerns around glucose metabolism — a clinical-safety characterization that predates the February 2026 and April 22, 2026 PCAC actions that have since narrowed 503A access for several compounds in this class. These compounds are not FDA-approved; no FDA-approved sermorelin, CJC-1295, or ipamorelin product is currently marketed in the United States. Current clinical access is through 503A pharmacy compounding from Category 1 bulk substances (sermorelin) or compounds subject to the April 22, 2026 PCAC recommendation (CJC-1295, ipamorelin). Use reflects the independent clinical judgment of the prescribing provider and has not been evaluated or endorsed by the FDA.

Tissue-repair peptides: BPC-157 and thymosin beta-4 [Preclinical / very limited human data]

BPC-157 and thymosin beta-4 have meaningful preclinical data but should not be represented as having established human clinical benefit. A 2025 systematic review by Vasireddi and colleagues in HSS Journal reviewed BPC-157 in orthopaedic sports medicine, finding preclinical evidence for musculoskeletal healing but explicitly noting the absence of human RCTs and clinical safety data. McGuire and colleagues, in a 2025 narrative review in Current Reviews in Musculoskeletal Medicine, framed BPC-157 as a compound whose preclinical benefits are untranslated to human trials. The most direct human clinical observation is from Lee and Padgett in a 2021 case series in Alternative Therapies in Health and Medicine: 11 of 12 patients with chronic knee pain who received BPC-157 alone reported significant improvement after intra-articular injection — a signal, but not evidence. As of April 2026, BPC-157 is designated an FDA Category 2 bulk drug substance under the February 2026 PCAC action, meaning it is not eligible for compounding under Section 503A pending further FDA review. Compounding by licensed 503A pharmacies is therefore not currently available for BPC-157.

Sexual health peptides: bremelanotide [Human RCT — FDA approved]

Bremelanotide is one of the clearest examples of a peptide that crossed from research into FDA approval. Pfaus and colleagues, reviewing the neurobiology of bremelanotide in CNS Spectrums in 2022, described its mechanism, which acts through central melanocortin pathways modulating sexual arousal in premenopausal women with HSDD. The FDA-approved indication is specific: hypoactive sexual desire disorder in premenopausal women who have not undergone surgical menopause. Use outside this indication is off-label and has not been evaluated through controlled trials.

Delivery Methods for Peptide Therapy

Subcutaneous injection

Most peptide therapies discussed in this article are administered by subcutaneous injection — delivered into the tissue just below the skin. This route provides reliable absorption into systemic circulation while preserving peptide structural integrity. GLP-1 agonists such as semaglutide and liraglutide, GH secretagogues, and bremelanotide are all subcutaneously administered. Providers or their clinical teams guide first-use technique and site rotation for subcutaneous protocols.

Oral formulations

Oral semaglutide (Rybelsus) uses SNAC permeation technology to enable absorption across the gastric mucosa — the only well-characterized oral peptide drug in this category with FDA approval. Most other therapeutic peptides are enzymatically degraded in the gastrointestinal tract before reaching systemic circulation, making oral delivery ineffective without specialized formulation. Oral "peptide supplements" marketed outside pharmaceutical frameworks are not equivalent to the injectable compounds discussed in clinical benefit-risk contexts.

Nasal spray

Some providers compound intranasal formulations of select peptides. Bremelanotide is FDA-approved as a subcutaneous auto-injector; some providers prescribe intranasal compounded formulations. Nasal delivery bypasses first-pass hepatic metabolism but provides more variable absorption than subcutaneous injection for most peptide classes. GH secretagogues and GLP-1 agonists are not delivered by nasal route in validated clinical protocols.

Topical and other routes

Topical peptide formulations are cosmetic products regulated by FDA cosmetics law. They are not therapeutic equivalents to injectable compounds and carry no FDA-evaluated systemic effect claims. Intravenous infusion is used for select compounds in supervised clinical settings and is not a self-administered route.

Safety and Side Effects

The side effect profile of peptide therapy reflects both the compound's inherent pharmacology and the context of its use — whether via a licensed provider with a product compounded under USP chapter standards by a licensed 503A pharmacy, or from an unregulated source.

Common side effects (typically mild to moderate, dose-dependent):

• Nausea, vomiting, diarrhea, constipation — primary adverse effects of GLP-1 receptor agonists; dose-dependent and typically attenuating with gradual titration over the first weeks of therapy
• Injection site reactions (redness, swelling, bruising) — applicable across all injectable peptide classes; most common in early weeks and typically self-limiting
• Water retention and transient peripheral edema — associated with GH-stimulating peptides; generally resolves with dose adjustment
• Headache or mild fatigue, particularly in the first 1 to 2 weeks of any new GH-stimulating therapy

Less common but clinically important:

• IGF-1 elevation above the reference range — GH secretagogue therapy requires monitoring IGF-1 at baseline and during therapy; supraphysiological IGF-1 is a dose-adjustment signal
• Impaired glucose tolerance or insulin resistance — documented with GH-axis peptides; a 2017 study by Sigalos and colleagues in the American Journal of Men's Health found GH secretagogue treatment raises IGF-1 levels in hypogonadal men — relevant both as a benefit proxy and as a monitoring target for glucose effects; baseline HbA1c is clinically indicated before starting
• Immunogenic reactions including anti-drug antibody formation — a 2025 review by Achilleos and colleagues in the Journal of Peptide Science noted that, between 2016 and 2024, 11% of new FDA pharmaceuticals were synthetic peptides, emphasising that immunogenicity remains a critical safety assessment for peptide therapeutics; risk is compound-specific and related to peptide structure, injection route, and dosing frequency
• Cholelithiasis (gallstone formation) — a monitored risk with GLP-1 class agents; hepatobiliary effects are included in FDA labeling for semaglutide and liraglutide

Risks specific to compounded and unregulated sources:

• Contamination — a 2018 analysis by Janvier and colleagues in Talanta reported purity ranging from 5% to 75% in cysteine-containing falsified polypeptide drug products, with arsenic (present in the more toxic inorganic form, at concentrations up to ten times the ICH toxicity limit for parenteral drugs) and lead contamination documented in samples; this represents contamination in grey-market products, not in compounds dispensed by licensed 503A pharmacies
• Incorrect dosing and compound misidentification — Vanhee and colleagues, writing in Talanta in 2015, documented incorrect dosing and misidentification in illegal peptide biopharmaceuticals seized by regulatory agencies
• Unknown degradation products — unregulated manufacturing does not include degradation product characterization; what a grey-market "peptide" contains beyond the labeled compound is not specified

When to contact your provider:

• Persistent injection site pain, warmth, spreading redness, or systemic fever
• Significant joint pain or water retention not responding to hydration or dose adjustment
• Cardiovascular symptoms — chest pain, palpitations, or shortness of breath at any time during therapy
• Unexpected fasting glucose changes, particularly in individuals with metabolic conditions
• Nausea or gastrointestinal symptoms that are severe or persistent beyond the typical adaptation period

Side effects are managed through dose titration and protocol review under provider supervision. The risk profile for any specific compound should be reviewed with a prescribing clinician before initiation.

What to Test Before Starting Peptide Therapy

Every peptide therapy produces biological changes that are only interpretable if a baseline measurement exists. Without pre-therapy labs, it is not possible to determine whether a lab change represents a therapeutic response, an adverse signal, or a pre-existing condition.

• IGF-1: The primary downstream marker of growth hormone axis activity — clinically mandatory before any GH secretagogue therapy. IGF-1 levels reflect the integrated GH secretory pattern and are the reference point against which any GH-related therapeutic response is measured. The Endocrine Society clinical practice guideline by Molitch 2006 established that GH axis evaluation requires IGF-1 testing before and during treatment.
• Fasting glucose: Baseline fasting glucose characterizes insulin sensitivity. GH secretagogues reduce insulin sensitivity; GLP-1 agonists lower fasting glucose in metabolic responders. Either direction of change is only interpretable against a baseline.
• HbA1c: Reflects average blood glucose over approximately 3 months. The primary glycemic endpoint in metabolic peptide clinical trials. A pre-therapy HbA1c is necessary for both GLP-1 agonist and GH secretagogue protocols.
• hs-CRP: Systemic inflammation baseline — particularly relevant for tissue-repair peptide contexts and for interpreting any cardiovascular risk signal during GLP-1 therapy.
• Triglycerides and lipid panel: GH-axis peptides affect fat metabolism; GLP-1 agonists often improve lipid parameters. A lipid baseline is standard before starting either class.
• Liver enzymes (ALT, AST): Hepatic function baseline; standard before injectable compounds processed hepatically.
• eGFR: Renal function affects clearance of injectable peptides. Impaired eGFR alters pharmacokinetics in ways that affect dosing and risk.

Setting up a biomarker test before any peptide therapy evaluation establishes the objective reference points that turn subsequent lab data into a clinically interpretable story.

What Your Labs May Show During Therapy

For GH secretagogue therapy, providers typically monitor IGF-1 (expected to increase toward the age-adjusted reference range in responders), fasting glucose (monitored for insulin sensitivity effects), and body composition clinically over 3 to 6 months. Hersch and Merriam, in a 2008 review in Clinical Interventions in Aging titled "Fountain of Youth or Pool of Tantalus?," weighed the anti-aging benefits of GH secretagogues against risks including glucose dysregulation and IGF-1 elevation — the same monitoring targets in current clinical practice. For GLP-1 agonist therapy, HbA1c and fasting glucose trend downward in metabolic responders; lipid panels often improve; cardiovascular markers are tracked in high-risk patients.

That monitoring principle — knowing your baseline to interpret any change — is central to Superpower's approach to preventive health. Peptide therapy decisions should begin with objective biomarker data and continue with systematic tracking of how those markers respond.

Regulatory Status and How to Access Peptide Therapy

FDA approval status

As of April 2026, the following peptide therapies carry FDA approval for specific indications: semaglutide (Ozempic, Wegovy) for type 2 diabetes and chronic weight management; tirzepatide (Mounjaro, Zepbound) for type 2 diabetes, chronic weight management, and moderate-to-severe obstructive sleep apnea in adults with obesity; tesamorelin for HIV-associated lipodystrophy; and bremelanotide for hypoactive sexual desire disorder. Sermorelin is available by prescription through licensed 503A compounding pharmacies following clinical evaluation by a licensed provider. CJC-1295 and ipamorelin were the subject of an April 22, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) recommendation against inclusion on the 503A bulk drug substances list; access through compounding pharmacies for these two peptides is subject to FDA's final determination and may be restricted. BPC-157 is designated an FDA Category 2 bulk drug substance under the February 2026 PCAC action, meaning it is not eligible for compounding under Section 503A pending further FDA review. Any off-label use of FDA-approved compounds or off-label prescription of compounded peptides reflects the independent clinical judgment of the prescribing physician and has not been evaluated or endorsed by the FDA.

Compounding access and 503A

As of April 2026, sermorelin is available by prescription through licensed 503A compounding pharmacies following clinical evaluation and remains in active compounding use. CJC-1295 and ipamorelin were the subject of an April 22, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) recommendation against inclusion on the 503A bulk drug substances list; access through compounding pharmacies for these two peptides is subject to FDA's final determination and may be restricted. Patients evaluating these compounds should confirm current availability directly with their licensed provider and the prescribing pharmacy. Tesamorelin (Egrifta, Egrifta SV) is a biologic licensed under the Public Health Service Act. Biologics licensed under section 351 of the PHS Act are generally not eligible for compounding from bulk substance under Section 503A, and Egrifta is not available as a compounded preparation; the FDA-approved product is the legal route of access in the United States. Semaglutide and tirzepatide compounding eligibility depends on current FDA shortage determinations and active enforcement guidance — access through compounding pharmacies is subject to regulatory change. As of April 2026, FDA shortage determinations for both semaglutide and tirzepatide have narrowed compounding access relative to the 2023–2024 period. Patients should confirm current availability directly with a licensed provider.

Cost and insurance framing

FDA-approved peptide medications for approved indications — semaglutide for obesity, tesamorelin for HIV lipodystrophy — may qualify for insurance coverage with prior authorization. Compounded GH secretagogues and off-label uses are typically not covered by insurance. HSA and FSA accounts may cover prescribed peptide therapy from a licensed provider. Cost varies significantly by compound, dosage, pharmacy, and branded versus compounded formulation. The evaluation process includes a clinical consultation and relevant lab work.

How to Evaluate a Provider for Peptide Therapy

A qualified provider for peptide therapy integrates clinical evaluation, baseline laboratory assessment, a pharmacy relationship with a licensed compounder, and a monitoring plan — before the first prescription. A provider who offers prescriptions without these elements is providing access without appropriate clinical oversight.

Questions to ask before starting with any provider:

• Which labs do you require before prescribing, and how will you use those results to assess my candidacy?
• How will you monitor my response and safety during therapy? How often will labs be repeated?
• Is this compound FDA-approved for the indication you are prescribing it for, or is it off-label?
• Which compounding pharmacy do you use? Is it licensed by its state board of pharmacy, operating under Section 503A, and compliant with USP <797> for sterile preparations (and ideally PCAB-accredited)?
• What is the plan if my labs show IGF-1 or glucose changes outside the expected range?

Superpower connects members with licensed providers who evaluate candidacy, prescribe where appropriate, and monitor response through ongoing lab work. Members considering GH secretagogue therapy can check eligibility through Superpower's sermorelin candidacy evaluation, which begins with a clinical consultation and baseline lab work.

Important Safety Information

This article discusses peptide compounds with varying FDA approval statuses. As of April 2026, FDA-approved peptide therapies discussed include semaglutide, tirzepatide, tesamorelin, and bremelanotide — each with specific approved indications. Uses outside those indications are off-label. BPC-157 is designated an FDA Category 2 bulk drug substance under the February 2026 PCAC action and is not eligible for compounding under Section 503A pending further FDA review. TB-500 (thymosin beta-4 acetate fragment 17–23) is designated Category 2 under the February 2026 PCAC action and is not eligible for compounding under Section 503A. It has no FDA-approved indication and limited human safety data.

Compounded GH secretagogues are not FDA-approved drugs. Sermorelin is prepared by state-licensed 503A compounding pharmacies following USP quality standards when prescribed by a licensed provider. CJC-1295 and ipamorelin were the subject of an April 22, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) recommendation against inclusion on the 503A bulk drug substances list; access through compounding pharmacies for these two peptides is subject to FDA's final determination and may be restricted. Any use of compounded GH secretagogues outside FDA-approved indications reflects the independent clinical judgment of the prescribing physician and has not been evaluated or endorsed by the FDA.

Superpower is a technology platform that connects members with licensed healthcare providers. Superpower does not prescribe medications or compound pharmaceutical products. Not all compounds discussed in this article are offered through licensed providers on the Superpower platform.

Grey-market research peptides purchased online without a prescription are not prepared under USP compounding standards or any regulated pharmacy oversight and have documented contamination and purity failures. This article's benefit discussion does not apply to such products.

For FDA-approved prescribing information, visit DailyMed. For FDA guidance on compounded peptides and bulk drug substance classifications, visit the FDA's compounding resource center.

Disclaimer: This page discusses multiple compounds with varying FDA approval statuses. Some compounds mentioned may not be FDA-approved for human use. Superpower Health offers some but not all compounds discussed. See individual compound pages for specific availability and regulatory status. This content is for educational and informational purposes only.